Abstract��OBJECTIVE To study the relativity between patients�� blood concentration of vancomycin and renal function, provide references for rational clinical application.METHODS The blood concentration and renal function of 64 cases of critical patients were monitored after the usage of vancomycin,then retrospectively analyzed combined with clinical date(basic information,bacteriological RESULTS ,clinical curative effect,etc.). RESULTS Pathogenic bacteria was detected from 40 of 64 patients, accounting for 62.5%. The effective rate of vancomycin reached 81.25%. The average value of 79 monitered cases of valley concentration was (17.48��13.22)��g��mL-1. There was no significant difference of the level of BUN and Scr before and after the treatment of vancomycin,while the level of Ccr had the significant difference. There were significant difference of the level of BUN, Scr, Ccr between the groups of valley concentration <5, 5-10, 10-20 ��g��mL-1 and the group of >20 ��g��mL-1. CONCLUSION The application of vancomycin in critical patients is relatively cautions.When using the drug,the drug concentration and renal function can be adjusted according to the RESULTS of blood concentration and renal function.
ZHU M,GUO D,LIU G Y, et al. Analysis on blood concentration monitoring of vancomycin and clinical administration behavior[J]. J China Pharm(�й�ҩ��),2010,21(14):1282-1285.
[2]
YE Z K, LI X G, ZHAI S D. Therapeutic drug monitoring of vancomycin in Chian:Current status and evaluation[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2013, 29(7):545-548.
[3]
HUAN Z Y, XIAO Y H, ZHANG J. Vancomycin clinical application of Chinese expert consensus(2011)[J]. Chin J New Drugs Clin Rem(�й���ҩ���ٴ���־), 2011, 30(8):561-573.
[4]
Measures for the management of clinical application of antibacterial drugs[S]. 2012-08-01.
[5]
JIANG H L, HE J, YANG W H. Critically ill patients with vancomycin for the adjustment of the dosage regimen is reviewed[J]. World Clin Drugs(�����ٴ�ҩ��), 2014, 35(7):439-443.
[6]
LI Q, HUAN Y, CAO D, et al. Analysis on blood concentration monitoring and influencing factors of digoxin in children[J]. Chin Pharm J(�й�ҩѧ��־), 2012, 47(10):795-797.
[7]
XIAO L, REN B, CHEN X L. Fluorescence polarization method for the determination of serum concentration of bancomycin[J]. J Qiqihar Med College(�������ҽѧԺѧ��),2007, 28(3):315-316.
[8]
LIU Z S, JIN D P, CHEN Z H. Hospital Infection Management(ҽԺ��Ⱦ����ѧ)[M]. Beijing:People��s Medical Publishing House, 2008:328.
[9]
HE X R, LU W, ZOU D, et al. Advance on population pharmacokinetic models of vancomycin[J]. Chin Pharm J(�й�ҩѧ��־), 2013, 48(24):2075-2080.
[10]
RYBAK M, LOMAESTRO B, ROTSCHAFER J C, et al. Therapeutic monitoring of vancomycin in adult patients:A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm, 2009, 66(1):82-98.
[11]
JI M C, SHEN X Y, YANG Y F. Progress in pharmacokinetics of vancomycin[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2008, 24(6):529.
[12]
KHWAJA A, KDIGO. Clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4):179-184.
[13]
COCKCROFT D W, GAULT M H. Prediction of creatinine clearance from serum creatinine[J]. Nephron, 1976, 16(1):31-41.
[14]
MA Y, WEI R X, QIAN N P, et al. Vancomycin in our blood drug concentration monitoring with clinical evaluation[J]. J China Pharm(�й�ҩ��), 2015, 26(5):622-625.
[15]
HIDAYAT L K, HSU D I, QUIST R, et al. High-dose vancomycin therapy formethicillin-resistant Staphylococcus aureus infections:Efficacy and toxicity[J]. Arch Intern Med, 2006, 166(19):2138-2144.
[16]
HU J L, ZHANG J. The research progress of vancomycin nephrotoxicity[J]. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2013, 13(5):394-399.
2016, Vol. 51 
